Frontlight ResearchEarly access
Active, not recruitingNo phase
Xeltis Peripheral Artery Disease (XPAD) Bypass Conduit Early Feasibility Study
Key facts
- Who runs it
- Xeltis
- Where
- Costa Rica1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 6 people, planned
- Started
- 2 May 2025
- Expected to end
- Dec 2028
- Type of study
- Interventional
- Treatments tested
- Xeltis Peripheral Artery Disease (XPAD) Bypass Conduit
- Record updated
- 6 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 27 criteriaShow less
Who can take part
- Subjects with femoral artery occlusion who require elective above-knee femoral popliteal bypass surgery
- Patient has Rutherford grade 3, 4, or 5 occlusive vascular disease and TASC C or D lesions. Rutherford grade 5 may be included with a wound, ischemia and foot infection (WiFi) classification of up to grade 2, provided there are two outflow vessels with at least one reaching the pedal arch
- At least 18 years of age at screening
- Suitable anatomy (assessed by a pre-procedural contrasted CT scan or previous angiogram assessed up to 90 days prior to baseline)
- Patient has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent
- Patient has been informed and agrees to pre- and post-procedure follow-up, including follow-up angiography
- Life expectancy of at least 24 months
Who cannot take part
- Stroke or myocardial infarction event within 6 weeks of the procedure or evidence of prior massive stroke (Modified Rankin Scale 3 or above)
- Previous renal transplant
- Previous enrolment in this study
- Unsuitable anatomy to implant the XPAD conduit (e.g. target vessel diameter smaller than anticipated; severe calcification)
- Subject requires, or is scheduled for, a cardiac surgical procedure or a different vascular surgical procedure within 30 days of study procedure
- Presence or history of bypass in the diseased limb
- History of acute arterial occlusion requiring an emergent intervention
- Uncontrolled arterial hypertension (BP >200 mmHg) at 2 successive readings
- Uncontrolled or poorly controlled diabetes
- Any active local or systemic infection
- Known active bleeding disorder and/or any coagulopathy or thromboembolic disease
- Allergies to study device (nitinol) or agents/medication, such as contrast agents or aspirin, that can't be controlled medically
- Any other condition which, in the judgement of the investigator would preclude adequate evaluation for the safety and performance of the study conduit; Intra-operative exclusion criteria:
- Severe chronic renal insufficiency (serum creatinine >2.5 mg/dL) or undergoing hemodialysis
- Reduced liver function, defined as: >2x the upper limit of normal for serum bilirubin, International Normalized Ratio (INR) >1.5 or prothrombin time (PT) >18 seconds
- Subject requires sequential extremity revascularizations or other procedures that require use of additional vascular grafts
- Abnormal blood values that could influence patient recovery and or/ graft hemostasis
- Known heparin-induced thrombocytopenia
- Subject is participating in another study
- Pregnant or breastfeeding woman or woman in fertile period not taking adequate contraceptives
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
A prospective, single arm, non-randomized early feasibility study to evaluate the preliminary safety and performance of the XPAD conduit in patients with peripheral arterial occlusive disease (PAOD), scheduled to undergo elective above-knee femoral popliteal bypass surgery.
The group in the trial
- XPAD Bypass ConduitTreatment being tested
Treatment: Xeltis Peripheral Artery Disease (XPAD) Bypass Conduit
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Prospective, Non-randomized, Early Feasibility Clinical Study to Assess the Feasibility of the Novel Xeltis Peripheral Artery Disease (XPAD) Bypass Conduit
- Record updated
- 6 October 2026